bupropion has been researched along with Acute Post-Traumatic Stress Disorder in 17 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was conducted to evaluate the effect of bupropion sustained-release (SR) on smoking cessation in patients with chronic posttraumatic stress disorder (PTSD)." | 9.09 | A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. ( Beckham, JC; Feldman, ME; Hertzberg, MA; Moore, SD, 2001) |
| "We report the case of a 22-year-old woman with bulimia nervosa and complex PTSD who abused bupropion XR to doses that at peak reached 3,000-4,500 mg/day." | 7.88 | Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD. ( Dagan, Y; Yager, J, 2018) |
| " All smokers received 2 smoking cessation counseling sessions, nicotine replacement, and bupropion." | 5.17 | Mobile contingency management as an adjunctive smoking cessation treatment for smokers with posttraumatic stress disorder. ( Beckham, JC; Calhoun, PS; Carpenter, VL; Dedert, EA; Dennis, MF; Dennis, PA; Hertzberg, JS; Kirby, AC; Moore, SD, 2013) |
| "This study was conducted to evaluate the effect of bupropion sustained-release (SR) on smoking cessation in patients with chronic posttraumatic stress disorder (PTSD)." | 5.09 | A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. ( Beckham, JC; Feldman, ME; Hertzberg, MA; Moore, SD, 2001) |
| "We report the case of a 22-year-old woman with bulimia nervosa and complex PTSD who abused bupropion XR to doses that at peak reached 3,000-4,500 mg/day." | 3.88 | Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD. ( Dagan, Y; Yager, J, 2018) |
| "Patients diagnosed with PTSD showed more severe depressive symptoms at baseline and were less likely to achieve either remission or response by 12 weeks." | 2.94 | Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. ( Aslam, M; Chen, P; Davis, L; Hicks, PB; Iranmanesh, A; Johnson, GR; Jurjus, G; Lauro, K; Michalets, J; Mohamed, S; Pilkinton, P; Rao, SD; Sapra, M; Sevilimedu, V; Thase, M; Wilcox, JA; Zisook, S, 2020) |
| "Bupropion SR in the treatment of PTSD had no significant effect in the current sample." | 2.73 | A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. ( Becker, ME; Beckham, JC; Bukenya, DS; Dennis, MF; Hertzberg, MA; Moore, SD, 2007) |
| " Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures." | 1.62 | Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. ( Brajcich, MR; Marks, J; Messer, RD; Murphy, ME; Palau, MA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, S | 1 |
| Johnson, GR | 1 |
| Sevilimedu, V | 1 |
| Rao, SD | 1 |
| Hicks, PB | 1 |
| Chen, P | 1 |
| Lauro, K | 1 |
| Jurjus, G | 1 |
| Pilkinton, P | 1 |
| Davis, L | 1 |
| Wilcox, JA | 1 |
| Iranmanesh, A | 1 |
| Sapra, M | 1 |
| Aslam, M | 1 |
| Michalets, J | 1 |
| Thase, M | 1 |
| Zisook, S | 1 |
| Brajcich, MR | 1 |
| Palau, MA | 1 |
| Messer, RD | 1 |
| Murphy, ME | 1 |
| Marks, J | 1 |
| Herr, J | 1 |
| Hatch, L | 1 |
| Sephien, A | 1 |
| Hanna, K | 1 |
| Dagan, Y | 1 |
| Yager, J | 1 |
| Hertzberg, JS | 1 |
| Carpenter, VL | 1 |
| Kirby, AC | 1 |
| Calhoun, PS | 2 |
| Moore, SD | 4 |
| Dennis, MF | 2 |
| Dennis, PA | 1 |
| Dedert, EA | 2 |
| Beckham, JC | 4 |
| Kojima, G | 1 |
| Tamai, A | 1 |
| Karino, S | 1 |
| Yuasa, M | 1 |
| Epure, J | 1 |
| Tsuzaki, B | 1 |
| Tanabe, M | 1 |
| Tidey, JW | 1 |
| Miller, ME | 1 |
| Szakaly, B | 1 |
| Strauss, R | 1 |
| Wilson, SM | 1 |
| Hamlett-Berry, KW | 1 |
| Bagley, SC | 1 |
| Yaeger, D | 1 |
| Becker, ME | 1 |
| Hertzberg, MA | 2 |
| Bukenya, DS | 1 |
| Dattilo, PB | 1 |
| Nordin, C | 1 |
| Swartz, CM | 1 |
| Guadagno, G | 1 |
| David, D | 1 |
| Esquenazi, J | 1 |
| Reeves, RM | 1 |
| Feldman, ME | 1 |
| Sullivan, MA | 1 |
| Covey, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)[NCT01421342] | Phase 3 | 1,522 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Relapse in symptoms of major depression defined as a QIDS-C16 => 11 among those achieving remission in the acute phase. (NCT01421342)
Timeframe: Within 36 weeks after randomization (initiation of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 26 |
| Augmenting: Antidepressant + Bupropion-SR | 35 |
| Augmenting: Antidepressant + Aripiprazole | 37 |
Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of <= 5 for two consecutive visits. (NCT01421342)
Timeframe: During acute phase (12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 114 |
| Augmenting: Antidepressant + Bupropion-SR | 136 |
| Augmenting: Antidepressant + Aripiprazole | 146 |
Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 319 |
| Augmenting: Antidepressant + Bupropion-SR | 332 |
| Augmenting: Antidepressant + Aripiprazole | 375 |
Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved). (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Switching: Bupropion-SR | 356 |
| Augmenting: Antidepressant + Bupropion-SR | 376 |
| Augmenting: Antidepressant + Aripiprazole | 400 |
3 reviews available for bupropion and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Smoking cessation and reduction in people with chronic mental illness.
Topics: Anxiety Disorders; Bipolar Disorder; Bupropion; Electronic Nicotine Delivery Systems; Humans; Mental | 2015 |
Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case.
Topics: Abscess; Adult; Anesthesia, Dental; Antidepressive Agents, Second-Generation; Bupropion; Dental Care | 2008 |
Nicotine dependence: the role for antidepressants and anxiolytics.
Topics: Alcoholism; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorde | 2002 |
6 trials available for bupropion and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Depre | 2020 |
Mobile contingency management as an adjunctive smoking cessation treatment for smokers with posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Bupropion; Combined Modality Ther | 2013 |
Hyponatremia associated with bupropion, a case verified by rechallenge.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Cocaine-Related D | 2005 |
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Bupropion; Chronic | 2007 |
Melancholia with onset during treatment with SSRIs.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Dis | 1998 |
A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Delayed-Action Preparat | 2001 |
8 other studies available for bupropion and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures.
Topics: Antidepressive Agents; Bipolar Disorder; Brain Diseases; Bupropion; Drug Therapy, Combination; Dyski | 2021 |
27-year-old woman • postpartum seizures • PTSD • history of depression • Dx?
Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression, Postpartum; Female; Humans; Seizure | 2021 |
Severe bupropion XR abuse in a patient with long-standing bulimia nervosa and complex PTSD.
Topics: Adult; Bulimia Nervosa; Bupropion; Female; Humans; Stress Disorders, Post-Traumatic; Young Adult | 2018 |
Bupropion-related visual hallucinations in a veteran with posttraumatic stress disorder and multiple sclerosis.
Topics: Aged, 80 and over; Bupropion; Dopamine Uptake Inhibitors; Fatigue; Hallucinations; Humans; Male; Mul | 2013 |
Public health clinical demonstration project for smoking cessation in veterans with posttraumatic stress disorder.
Topics: Bupropion; Cohort Studies; Counseling; Delivery of Health Care; Health Promotion; Hotlines; Humans; | 2010 |
Prolonged QT associated with an overdose of trazodone.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Drug Overdose; Electrocardio | 2007 |
Rhabdomyolysis associated with bupropion treatment.
Topics: Bupropion; Humans; Liver Diseases; Male; Middle Aged; Rhabdomyolysis; Stress Disorders, Post-Traumat | 1999 |
Omission of bupropion as a recommended treatment for PTSD.
Topics: Bupropion; Drug Industry; Expert Testimony; Humans; Practice Guidelines as Topic; Research Support a | 2000 |